EUVIMEDEUVIMED entdecken
Crossref

First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial

Tian Wang, Xiang Liu, Jie Wang, Tianci Tang, Weifang Wang, Xiaoshen Wang, Xinmao Song, Hao Ding

Clinical Lymphoma Myeloma and Leukemia · 2026-11

DOI: 10.1016/j.clml.2026.10.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Tian Wang und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wang, T., Liu, X., Wang, J., Tang, T., Wang, W., Wang, X., Song, X., & Ding, H. (2026). First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.025

Vancouver

Wang T, Liu X, Wang J, Tang T, Wang W, Wang X, et al. First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.025

BibTeX
@article{Wang2026,
  author = {Wang, Tian and Liu, Xiang and Wang, Jie and Tang, Tianci and Wang, Weifang and Wang, Xiaoshen and Song, Xinmao and Ding, Hao},
  title = {First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.025}
}
Kostenlos starten →